Shenlian Biotech announced that the 9th meeting of the fourth board of directors of the company reviewed and passed the bill and agreed to appoint Gao Xu as the company's deputy general manager. The term of office will begin on the date of review and approval by the board of directors and end on the date the term of the fourth board of directors expires. Gao Xu has more than 30 years of experience in the veterinary biological products industry. He joined the company in 2007 and is familiar with the company's entire R&D, production and sales chain business. As of the disclosure date of the announcement, Gao Xu did not directly hold shares in the company. He indirectly held about 825 million shares of the company through the Shanghai Shentailian Investment Partnership. He had no relationship with shareholders holding 5% or more of the company's shares or other directors or senior management, and his qualifications met the relevant regulations.

Shenlian Biotech announced that the 9th meeting of the fourth board of directors of the company reviewed and passed the bill and agreed to appoint Gao Xu as the company's deputy general manager. The term of office will begin on the date of review and approval by the board of directors and end on the date the term of the fourth board of directors expires. Gao Xu has more than 30 years of experience in the veterinary biological products industry. He joined the company in 2007 and is familiar with the company's entire R&D, production and sales chain business. As of the disclosure date of the announcement, Gao Xu did not directly hold shares in the company. He indirectly held about 825 million shares of the company through the Shanghai Shentailian Investment Partnership. He had no relationship with shareholders holding 5% or more of the company's shares or other directors or senior management, and his qualifications met the relevant regulations.